Are You a Patient Taking Vidaza or Dacogen?Posted: February 8, 2016 Filed under: Clinical Trials, CRUSH!!MDS, Laboratory Research, Patient Education, Uncategorized | Tags: Blood Disorders, dacogen, Gail Roboz, Leukemia Treatment, MDS, Myelodysplastic Syndrome, vidaza, Weill Cornell, Weill Cornell Leukemia Program Comments Off on Are You a Patient Taking Vidaza or Dacogen?
Seeking Research Volunteers
Predicting Response To Your Myelodysplastic Syndrome (MDS) Treatment
Azacitidine (Vidaza®) and decitabine (Dacogen®) are FDA-approved drugs for the treatment of MDS. While these drugs help many patients with MDS, sometimes patients who initially respond to these drugs eventually lose their response. Why? Why do the drugs stop working? MDS-CRC investigators are trying to answer this question. Through CRUSH!!MDS, we are recruiting patients who have not responded or lost their initial response to azacitidine or decitabine. Patients will be able to have blood drawn at the time of a routine visit to their local doctor and we will arrange for the blood to be delivered to Weill Cornell Medical College, at no cost to the patient. At Weill Cornell, the blood will be analyzed in the laboratory of Dr. Joseph Scandura, M.D.
For more information about the study and the CRUSH!!MDS initiative, please visit our website.